Institution
European Monitoring Centre for Drugs and Drug Addiction
Government•Lisbon, Portugal•
About: European Monitoring Centre for Drugs and Drug Addiction is a government organization based out in Lisbon, Portugal. It is known for research contribution in the topics: European union & Population. The organization has 95 authors who have published 300 publications receiving 16972 citations. The organization is also known as: EMCDDA.
Topics: European union, Population, Poison control, Cannabis, Heroin
Papers published on a yearly basis
Papers
More filters
••
Dresden University of Technology1, Centre for Addiction and Mental Health2, Karlstad University3, Stockholm School of Economics4, University of Copenhagen5, Karolinska Institutet6, University of Florence7, University of Basel8, University of Zurich9, Maastricht University10, University of Lausanne11, European Monitoring Centre for Drugs and Drug Addiction12, Aarhus University Hospital13
TL;DR: The true size and burden of disorders of the brain in the EU was significantly underestimated in the past, and Concerted priority action is needed at all levels, including substantially increased funding for basic, clinical and public health research and policy decisions.
3,079 citations
••
Karlstad University1, Dresden University of Technology2, Karolinska University Hospital3, Mental Health Services4, Phillips University5, University of Florence6, Karolinska Institutet7, John Radcliffe Hospital8, London School of Economics and Political Science9, King's College London10, Lund University11, Harvard University12, University of Basel13, Norwegian University of Science and Technology14, University of Zurich15, Umeå University16, University of Cambridge17, University of Lausanne18, University of Sassari19, European Monitoring Centre for Drugs and Drug Addiction20, Aalborg University21, Cliniques Universitaires Saint-Luc22, Maastricht University Medical Centre23, Radboud University Nijmegen24, Stockholm School of Economics25
TL;DR: The present report presents much improved cost estimates for the total cost of disorders of the brain in Europe in 2010, covering 19 major groups of disorders, 7 more than previously, of an increased range of age groups and more cost items.
1,325 citations
••
TL;DR: Improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs, however, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm.
1,298 citations
••
TL;DR: The high prevalence of HIV among many populations of injecting drug users represents a substantial global health challenge and existing data are far from adequate, in both quality and quantity.
1,192 citations
••
TL;DR: Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids.
Abstract: Objective To compare the risk for all cause and overdose mortality in people with opioid dependence during and after substitution treatment with methadone or buprenorphine and to characterise trends in risk of mortality after initiation and cessation of treatment.
Design Systematic review and meta-analysis.
Data sources Medline, Embase, PsycINFO, and LILACS to September 2016.
Study selection Prospective or retrospective cohort studies in people with opioid dependence that reported deaths from all causes or overdose during follow-up periods in and out of opioid substitution treatment with methadone or buprenorphine.
Data extraction and synthesis Two independent reviewers performed data extraction and assessed study quality. Mortality rates in and out of treatment were jointly combined across methadone or buprenorphine cohorts by using multivariate random effects meta-analysis.
Results There were 19 eligible cohorts, following 122 885 people treated with methadone over 1.3-13.9 years and 15 831 people treated with buprenorphine over 1.1-4.5 years. Pooled all cause mortality rates were 11.3 and 36.1 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 3.20, 95% confidence interval 2.65 to 3.86) and reduced to 4.3 and 9.5 in and out of buprenorphine treatment (2.20, 1.34 to 3.61). In pooled trend analysis, all cause mortality dropped sharply over the first four weeks of methadone treatment and decreased gradually two weeks after leaving treatment. All cause mortality remained stable during induction and remaining time on buprenorphine treatment. Overdose mortality evolved similarly, with pooled overdose mortality rates of 2.6 and 12.7 per 1000 person years in and out of methadone treatment (unadjusted out-to-in rate ratio 4.80, 2.90 to 7.96) and 1.4 and 4.6 in and out of buprenorphine treatment.
Conclusions Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids. The induction phase onto methadone treatment and the time immediately after leaving treatment with both drugs are periods of particularly increased mortality risk, which should be dealt with by both public health and clinical strategies to mitigate such risk. These findings are potentially important, but further research must be conducted to properly account for potential confounding and selection bias in comparisons of mortality risk between opioid substitution treatments, as well as throughout periods in and out of each treatment.
1,114 citations
Authors
Showing all 95 results
Name | H-index | Papers | Citations |
---|---|---|---|
Paul De Grauwe | 62 | 487 | 14878 |
Paul Griffiths | 48 | 138 | 8293 |
Lucas Wiessing | 36 | 91 | 6170 |
Marica Ferri | 22 | 61 | 3547 |
V. Anna Gyarmathy | 21 | 58 | 1239 |
Leslie A. King | 19 | 33 | 4256 |
Dagmar Hedrich | 18 | 37 | 1325 |
Roumen Sedefov | 18 | 40 | 1492 |
Carole Seguin-Devaux | 17 | 49 | 2943 |
Michael Evans-Brown | 17 | 35 | 980 |
Teodora Groshkova | 16 | 32 | 1166 |
Isabelle Giraudon | 15 | 40 | 883 |
Björn Hibell | 14 | 18 | 2796 |
Julian Vicente | 14 | 36 | 825 |
Henri Bergeron | 12 | 65 | 544 |